SCHEMBL9544613

SCHEMBL9544613

CC(O)(COCc1ccccc1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.48
TACR1 P25103 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA1 P00915 3/20 0.41
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CES1 P23141 2/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29514402 0.88 KDM4E (0.46) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL16391417 0.82 KDM4E (0.50) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL476765 0.81 KDM4E (0.53) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL18640775 0.81 TSHR (0.56) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL95926 0.81 KDM4E (0.56) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL13557891 0.81 KDM4E (0.56) KDM4EPOLBTSHRTACR1ALDH1A1
Boric Acid SCHEMBL29765260 0.81 KDM4E (0.49) KDM4EPOLBTSHRTACR1ALDH1A1
SCHEMBL18561111 0.79 ALDH1A1 (0.39) KDM4EPOLBTACR1ALDH1A1MEN1
Tert-Butanol SCHEMBL27883617 0.78 TSHR (0.71) KDM4EPOLBTSHRALDH1A1CA1
SCHEMBL13888734 0.78 KDM4E (0.46) KDM4EPOLBTSHRTACR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5178778-A None JP disclosed
US-20170298055-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-20170298055-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-20170298055-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
WO-2016044445-A2 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-03-24 WO disclosed
WO-2016044445-A2 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-03-24 WO disclosed
JP-H05178778-A TERTIARY ALCOHOL COMPOUND HAVING TRIFLUOROMETHYL GROUP AND ITS PRODUCTION NIKKO KYODO CO LTD 1993-07-20 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298055-A1 sGC STIMULATORS GUCY1B1, GUCY1A1, PRKG2 KDM4E 1724/4885POLB 4027/4885TSHR 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.